drugset / Trial / NCT02169440

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

NCT02169440

Phase 1 Completed 20 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.

Timeline

Start
2009-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 25 mg
Subject Warfarin Small molecule 25 mg

Indications